6 articles published in JoVE

• Cancer Research

  
  Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel Lisa Mohr¹, Marc Carceles-Cordon¹, Jungreem Woo¹, Carlos Cordon-Cardo¹, Josep Domingo-Domenech¹, Veronica Rodriguez-Bravo^{1,2 1}Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, ²Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Resistance to cancer therapies contributes to disease progression and death. Determining the mechanistic underpinnings of resistance is crucial for improving therapeutic response. This manuscript details the protocol to generate taxane-resistant cell models of prostate cancer (PC) to help dissecting the pathways involved in progression to Docetaxel resistance in PC patients.

• Cancer Research

  
  Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel Lisa Mohr¹, Marc Carceles-Cordon¹, Jungreem Woo¹, Carlos Cordon-Cardo¹, Josep Domingo-Domenech¹, Veronica Rodriguez-Bravo^{1,2 1}Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, ²Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Resistance to cancer therapies contributes to disease progression and death. Determining the mechanistic underpinnings of resistance is crucial for improving therapeutic response. This manuscript details the protocol to generate taxane-resistant cell models of prostate cancer (PC) to help dissecting the pathways involved in progression to Docetaxel resistance in PC patients.

• Behavior

  
  Novel Object Recognition Test for the Investigation of Learning and Memory in Mice Lindsay M. Lueptow^{1 1}Pharmacological Sciences, Icahn School of Medicine at Mount Sinai The object recognition test (ORT) is a simple and efficient assay for evaluating learning and memory in mice. The methodology is described below.

• Immunology and Infection

  
  Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies Paul E. Leon^1,2, Teddy John Wohlbold^1,2, Wenqian He^1,2, Mark J. Bailey^1,2, Carole J. Henry³, Patrick C. Wilson³, Florian Krammer¹, Gene S. Tan^{1 1}Department of Microbiology, Icahn School of Medicine at Mount Sinai, ²Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, ³The Department of Medicine, Section of Rheumatology, The Knapp Center for Lupus and Immunology Research, The University of Chicago We describe a method by which we identify critical residues required for the binding of human or murine monoclonal antibodies that target the viral hemagglutinin of influenza A viruses. The protocol can be adapted to other virus surface glycoproteins and their corresponding neutralizing antibodies.

• Immunology and Infection

  
  Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies Paul E. Leon^1,2, Teddy John Wohlbold^1,2, Wenqian He^1,2, Mark J. Bailey^1,2, Carole J. Henry³, Patrick C. Wilson³, Florian Krammer¹, Gene S. Tan^{1 1}Department of Microbiology, Icahn School of Medicine at Mount Sinai, ²Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, ³The Department of Medicine, Section of Rheumatology, The Knapp Center for Lupus and Immunology Research, The University of Chicago We describe a method by which we identify critical residues required for the binding of human or murine monoclonal antibodies that target the viral hemagglutinin of influenza A viruses. The protocol can be adapted to other virus surface glycoproteins and their corresponding neutralizing antibodies.

• Cancer Research

  
  A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines Jun Tang¹, Carlos Pérez-Medina^1,2, Yiming Zhao², Ahmad Sadique¹, Willem J. M. Mulder², Thomas Reiner^{1 1}Department of Radiology, Memorial Sloan Kettering Cancer Center, ²Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai The poor understanding of the in vivo performance of nanomedicines stymies their clinical translation. Procedures to evaluate the in vivo behavior of cancer nanomedicines at systemic, tissue, single-cell, and subcellular levels in tumor-bearing immunocompetent mice are described here. This approach may help researchers to identify promising cancer nanomedicines for clinical translation.